 | Earn 30,000 American Airlines AAdvantage® Bonus Miles* Plus...
• First Checked Bag Free*
• Priority Boarding Privileges*
• Double Miles on Eligible Business Purchases*
• 25% savings on Eligible in-flight Purchases*
*Learn more. |
  | Health Care & Policy |  |  | | - FDA OKs NPS Pharmaceuticals' Gattex for short bowel syndrome
NPS Pharmaceuticals obtained FDA approval for Gattex, or teduglutide, as a treatment for short bowel syndrome, but the agency also asked the firm to conduct a study on the potential side effects of the drug. Gattex may raise a person's risk for cancer, intestinal blockages and polyps, the FDA said. NPS is expected to market the drug in March. Bloomberg Businessweek (12/21)       - FDA clears Alexza's Adasuve for agitation
The FDA approved Alexza Pharmaceuticals' Adasuve Inhalation Powder as an acute treatment for adults with agitation linked to schizophrenia or bipolar disorder. Adasuve uses the company's Staccato system to deliver the antipsychotic loxapine to the lungs as an aerosol. Alexza plans to launch the drug in the third quarter. RTT News (12/21) - EU approves Novartis' iron overload drug Exjade
The European Commission has granted Novartis approval for Exjade, or deferasirox, to reduce iron overload in patients with nontransfusion-dependent thalassemia syndrome receiving chelation treatment. The approval was based on a study that showed use of deferasirox can lead to significant dose-dependent reduction in iron levels in the body. RTT News (12/21) - 2nd-gen testosterone assay from Abbott gets FDA OK
Abbott has been cleared by the FDA to market its Architect 2nd Generation Testosterone Assay, which is used to measure testosterone in human plasma and serum quantitatively. The chemiluminescent microparticle immunoassay is designed to help detect and treat conditions such as male impotence, hypogonadism and advanced or delayed puberty. Healio (12/20) | Company & Financial News | | | | - Nuron raises $80M to advance vaccine and biologic drug candidates
Nuron Biotech obtained $80 million in private investment from Healthcare Royalty Partners. The amount included a $30 million equity investment and a $50 million "synthetic royalty" deal linked to future sales of Nuron's products. The firm plans to use the money to fund the market launch and expansion of its recently acquired vaccine, Meningitec, and to further develop investigational biologics and vaccines for neurodegenerative and infectious diseases. American City Business Journals/Philadelphia (12/20) | Food & Agriculture | | | | - Biotech salmon is safe to eat, FDA says
AquaBounty Technology's transgenic salmon poses no human or environmental health risks, the FDA said in a draft environmental evaluation. The review brings AquAdvantage salmon eggs closer to regulatory approval. "With respect to food safety, FDA has concluded that food from AquAdvantage salmon is as safe as food from conventional Atlantic salmon, and that there is a reasonable certainty of no harm from consumption," according to the draft. Reuters (12/21) | Hot Topics | | | | Top five news stories selected by BIO SmartBrief readers in the past week. - Results based on number of times each story was clicked by readers.
| Industrial & Environmental | | | | - Expert: Renewable fuels industry abuzz with new projects
The renewable fuels sector is touting "a splash of new refining projects, and steel in the ground," writes Jim Lane. Renewable fuels developers announced four major development projects in low-cost enzymes and in road and aviation fuels after "a year of dire headlines in government spending, renewable fuel mandates and so on," Lane writes. BiofuelsDigest.com (12/20)  | |  | | The Buzz(CORPORATE ANNOUNCEMENTS)
| |  | |  |
| News from BIO | | | | - Are you taking full advantage of your membership?
BIO's cost-savings program, BIO Business Solutions, is helping 2,700 companies nationwide save on the cost of essential products and services. Members of BIO and 43 state and regional biotech associations are eligible to receive preferential pricing and other benefits at no additional cost beyond their membership dues. VWR International, FedEx, Office Depot and Business Wire are just a few of the industry leading providers that offer special pricing through this members-only program. Learn more or enroll here.
| Editor's Note | | | | - SmartBrief will not publish Tuesday
In observance of Christmas, SmartBrief will not publish Tuesday. Publication will resume Wednesday. Enjoy the holiday! | SmartQuote | | | |  | In seed time learn, in harvest teach, in winter enjoy."
--William Blake,
British poet and painter  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Friday, December 21, 2012
- Thursday, December 20, 2012
- Wednesday, December 19, 2012
- Tuesday, December 18, 2012
- Monday, December 17, 2012
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2012 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment